MicroRNA expression profiles associated with mutational status and survival in malignant melanoma

Stefano Caramuta, Suzanne Egyházi, Monica Rodolfo, Daniela Witten, Johan Hansson, Catharina Larsson, Weng Onn Lui

Research output: Contribution to journalArticle

Abstract

Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in early melanoma diagnosis, the 5-year survival rate remains low in advanced disease. Therefore, novel biomarkers are urgently needed to devise new means of detection and treatment. In this study, we aimed to improve our understanding of microRNA (miRNA) deregulation in melanoma development and their impact on patient survival. Global miRNA expression profiles of a set of melanoma lymph node metastases, melanoma cell lines, and melanocyte cultures were determined using Agilent array. Deregulated miRNAs were evaluated in relation with clinical characteristics, patient survival, and mutational status for BRAF and NRAS. Several miRNAs were differentially expressed between melanocytes and melanomas as well as melanoma cell lines. In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation. Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survival. In conclusion, our findings show miRNA dysregulation in malignant melanoma and its relation to established molecular backgrounds of BRAF and NRAS oncogenic mutations. The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice.

Original languageEnglish
Pages (from-to)2062-2070
Number of pages9
JournalJournal of Investigative Dermatology
Volume130
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

MicroRNAs
Melanoma
Survival
Melanocytes
Cells
Deregulation
Biomarkers
Cell Line
Cell culture
Mutation
Skin Neoplasms
Skin
Classifiers
Early Diagnosis
Survival Rate
Lymph Nodes
Neoplasm Metastasis

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. / Caramuta, Stefano; Egyházi, Suzanne; Rodolfo, Monica; Witten, Daniela; Hansson, Johan; Larsson, Catharina; Lui, Weng Onn.

In: Journal of Investigative Dermatology, Vol. 130, No. 8, 08.2010, p. 2062-2070.

Research output: Contribution to journalArticle

Caramuta, Stefano ; Egyházi, Suzanne ; Rodolfo, Monica ; Witten, Daniela ; Hansson, Johan ; Larsson, Catharina ; Lui, Weng Onn. / MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. In: Journal of Investigative Dermatology. 2010 ; Vol. 130, No. 8. pp. 2062-2070.
@article{d031551cdafe47049495fb22ee7f5a2f,
title = "MicroRNA expression profiles associated with mutational status and survival in malignant melanoma",
abstract = "Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in early melanoma diagnosis, the 5-year survival rate remains low in advanced disease. Therefore, novel biomarkers are urgently needed to devise new means of detection and treatment. In this study, we aimed to improve our understanding of microRNA (miRNA) deregulation in melanoma development and their impact on patient survival. Global miRNA expression profiles of a set of melanoma lymph node metastases, melanoma cell lines, and melanocyte cultures were determined using Agilent array. Deregulated miRNAs were evaluated in relation with clinical characteristics, patient survival, and mutational status for BRAF and NRAS. Several miRNAs were differentially expressed between melanocytes and melanomas as well as melanoma cell lines. In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation. Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survival. In conclusion, our findings show miRNA dysregulation in malignant melanoma and its relation to established molecular backgrounds of BRAF and NRAS oncogenic mutations. The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice.",
author = "Stefano Caramuta and Suzanne Egyh{\'a}zi and Monica Rodolfo and Daniela Witten and Johan Hansson and Catharina Larsson and Lui, {Weng Onn}",
year = "2010",
month = "8",
doi = "10.1038/jid.2010.63",
language = "English",
volume = "130",
pages = "2062--2070",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - MicroRNA expression profiles associated with mutational status and survival in malignant melanoma

AU - Caramuta, Stefano

AU - Egyházi, Suzanne

AU - Rodolfo, Monica

AU - Witten, Daniela

AU - Hansson, Johan

AU - Larsson, Catharina

AU - Lui, Weng Onn

PY - 2010/8

Y1 - 2010/8

N2 - Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in early melanoma diagnosis, the 5-year survival rate remains low in advanced disease. Therefore, novel biomarkers are urgently needed to devise new means of detection and treatment. In this study, we aimed to improve our understanding of microRNA (miRNA) deregulation in melanoma development and their impact on patient survival. Global miRNA expression profiles of a set of melanoma lymph node metastases, melanoma cell lines, and melanocyte cultures were determined using Agilent array. Deregulated miRNAs were evaluated in relation with clinical characteristics, patient survival, and mutational status for BRAF and NRAS. Several miRNAs were differentially expressed between melanocytes and melanomas as well as melanoma cell lines. In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation. Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survival. In conclusion, our findings show miRNA dysregulation in malignant melanoma and its relation to established molecular backgrounds of BRAF and NRAS oncogenic mutations. The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice.

AB - Malignant cutaneous melanoma is a highly aggressive form of skin cancer. Despite improvements in early melanoma diagnosis, the 5-year survival rate remains low in advanced disease. Therefore, novel biomarkers are urgently needed to devise new means of detection and treatment. In this study, we aimed to improve our understanding of microRNA (miRNA) deregulation in melanoma development and their impact on patient survival. Global miRNA expression profiles of a set of melanoma lymph node metastases, melanoma cell lines, and melanocyte cultures were determined using Agilent array. Deregulated miRNAs were evaluated in relation with clinical characteristics, patient survival, and mutational status for BRAF and NRAS. Several miRNAs were differentially expressed between melanocytes and melanomas as well as melanoma cell lines. In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation. Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survival. In conclusion, our findings show miRNA dysregulation in malignant melanoma and its relation to established molecular backgrounds of BRAF and NRAS oncogenic mutations. The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=77954758320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954758320&partnerID=8YFLogxK

U2 - 10.1038/jid.2010.63

DO - 10.1038/jid.2010.63

M3 - Article

C2 - 20357817

AN - SCOPUS:77954758320

VL - 130

SP - 2062

EP - 2070

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 8

ER -